IQNavigator and Allegis Group Services Announce European Partnership
20.6.2011 07:59:49 CEST | Business Wire | Press release
IQNavigator is now an Allegis Group Services’ Preferred Software Partner for European MSP Customers
IQNavigator Inc. and Allegis Group Services (AGS) have formed a new partnership for AGS’s Managed Services Provider (MSP) customers in Europe. IQNavigator’s award-winning suite of applications for sourcing, engaging, managing and measuring the temporary workforce, consulting and other procured services is an ideal complement to AGS’s best-in-class workforce management solutions. Through this partnership, Allegis and IQNavigator will offer European companies an integrated and complete solution that addresses all of their contingent workforce management needs.
“IQNavigator renewed our US partnership with AGS in early 2010, and since then we have worked closely to provide an integrated best-in-class offering to meet customers’ extended workforce management needs. That collaboration has been such a success that AGS and IQNavigator have extended the partnership into Europe,” said Lou Andreozzi, President and CEO of IQNavigator. “This is great news for AGS’s European customers that require a services procurement platform to better manage project-based consultants, contractors and other temporary workers.”
“AGS’s global strategy is moving ahead quickly, and we are particularly excited by the growth opportunities in Europe,” said Chad Lane, President of AGS. “IQNavigator’s leading global software technology and their unparalleled ability to implement in complex situations have delivered significant benefits both to customers and our operations, and this agreement means that together we can provide a great solution to the European market.”
About Allegis Group Services
Allegis Group Services, Inc., headquartered in Hanover, MD, an operating company of Allegis Group, Inc., provides human capital and workforce management solutions to customers in a wide range of industries across the globe. Their offerings include Managed Services (MSP), Recruitment Process Outsourcing (RPO), Executive Search and Consulting Services.
Allegis Group Services can help optimize the use of your contingent workforce program, directly manage your organization’s recruitment needs and analyze key market trends to better serve your business needs. Through distinct service offerings, Allegis Group Services’ utilizes industry best practices and is experienced in assisting customers maximize the efficiency and effectiveness of their workforce programs. Transforming the Way the World Acquires Talent. Visit www.allegisgroupservices.com to learn more.
About IQNavigator
IQNavigator provides software and services that help the world’s best companies manage their extended workforce and procured services in a smarter way — putting the emphasis on “IQ” by giving companies powerful insight into and control over the way they source services and utilize their extensive non-employee workforce. Companies in every sector of the economy and every corner of the world are supplementing their permanent workforce with an extended workforce that enables them to leverage specialized skills, respond quickly to market opportunities, and maintain flexibility in the way they grow.
Services procurement and an extended workforce present significant challenges to companies, however, in areas such as visibility, cost control and risk. For more than a decade, IQNavigator has been at the forefront of the industry in providing the software solutions that address issues inherent with services procurement and extended workforce management, turning those challenges into opportunities for companies to become more nimble, reduce risk and save millions of dollars. For more information about IQNavigator and how its industry-leading offerings such as IQNtelligence are helping many of the world’s most respected companies, visit www.IQNavigator.com .
Contact:
Downing Street ~ A Communications Consultancy
Rich Miller,
303-877-3966
rich@downingstreetcommunications.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom